Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GI001 in r/r B-NHL
NCT07584850Phase 1Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Apr 2026
- Primary completion
- Jul 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of GI001 in B-cell non-Hodgkin lymphoma and B-cell leukemia (BCL), sponsored by Ruijin Hospital. Primary endpoints: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) and 5 more. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
GI001
03
Conditions
B-cell non-Hodgkin lymphomaB-cell leukemia (BCL)
Beyond the preview
Go deeper on NCT07584850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07584850.